NZ709685A - Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer - Google Patents

Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Info

Publication number
NZ709685A
NZ709685A NZ70968514A NZ70968514A NZ709685A NZ 709685 A NZ709685 A NZ 709685A NZ 70968514 A NZ70968514 A NZ 70968514A NZ 70968514 A NZ70968514 A NZ 70968514A NZ 709685 A NZ709685 A NZ 709685A
Authority
NZ
New Zealand
Prior art keywords
inorganic nanoparticles
ionizing radiations
combination
treating cancer
nanoparticles
Prior art date
Application number
NZ70968514A
Inventor
Elsa Borghi
Laurent Levy
Agnès Pottier
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Priority to NZ750194A priority Critical patent/NZ750194A/en
Priority claimed from PCT/EP2014/051367 external-priority patent/WO2014114732A1/en
Publication of NZ709685A publication Critical patent/NZ709685A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.
NZ70968514A 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer NZ709685A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ750194A NZ750194A (en) 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756533P 2013-01-25 2013-01-25
EP13305087 2013-01-25
PCT/EP2014/051367 WO2014114732A1 (en) 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Publications (1)

Publication Number Publication Date
NZ709685A true NZ709685A (en) 2019-10-25

Family

ID=67296872

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ750194A NZ750194A (en) 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
NZ70968514A NZ709685A (en) 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ750194A NZ750194A (en) 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Country Status (9)

Country Link
DK (1) DK2948179T3 (en)
ES (1) ES2734493T3 (en)
HR (1) HRP20191272T1 (en)
HU (1) HUE045407T2 (en)
LT (1) LT2948179T (en)
NZ (2) NZ750194A (en)
PT (1) PT2948179T (en)
SG (1) SG10202105500VA (en)
TR (1) TR201910251T4 (en)

Also Published As

Publication number Publication date
NZ750194A (en) 2020-02-28
TR201910251T4 (en) 2019-07-22
PT2948179T (en) 2019-07-19
HRP20191272T1 (en) 2019-10-18
DK2948179T3 (en) 2019-07-22
HUE045407T2 (en) 2019-12-30
SG10202105500VA (en) 2021-07-29
ES2734493T3 (en) 2019-12-10
LT2948179T (en) 2019-08-12

Similar Documents

Publication Publication Date Title
MX2015009409A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer.
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2016007351A (en) Combination therapy for treating cancer.
MX2019001920A (en) Rna for cancer therapy.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2019010601A (en) Combination therapy for treating cancer.
NZ749218A (en) Androgen receptor modulator and uses thereof
SG10201902664RA (en) Combination therapy for treating cancer
WO2015009726A3 (en) Medical uses of cd38 agonists
WO2016043874A3 (en) Combination therapy for treating cancer
MX2016009069A (en) Duocarmycin adcs for use in treatment of endometrial cancer.
BR112015026297A2 (en) combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment
MX2015012922A (en) Cancer treatment using antibodies that bing cell surface grp78.
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
MX2020001727A (en) Combination therapy.
MX2019013862A (en) Combination therapy.
MX2023007706A (en) Nanoparticles for use as a therapeutic vaccine.
MX2018000052A (en) Compositions and methods for combination therapy with dengue virus and dendritic cells.
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
NZ750194A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
MX2021001081A (en) Combination therapy for treating cancer.
MX2019014934A (en) Methods of treating brain tumors using combination therapy.
MX2019014842A (en) Methods of treating brain tumors using combination therapy.
MX2017013668A (en) Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2022 BY IPAN GMBH

Effective date: 20210104

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2023 BY IPAN GMBH

Effective date: 20220107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2024 BY IPAN GMBH

Effective date: 20230103

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2025 BY IPAN GMBH

Effective date: 20240117